Here are the S-3 shelf registrations from Cadrenal Therapeutics, Inc. (CVKD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics, Inc. is registering up to 2,942,400 shares of common stock for resale by existing securityholders. The shares consist of 2,880,000 shares issuable upon exercise of pre-funded and Series C-1/C-2 warrants from a July 1, 2026 PIPE financing and 62,400 shares underlying placement agent warrants.
The company will not receive proceeds from stockholder resales, but would receive approximately $5.8 million from cash exercises of Investor Warrants and $244,000 from exercises of Placement Agent Warrants, intended for working capital and general corporate purposes. Registered shares would equal 49% of outstanding stock upon issuance (3,098,592 shares were outstanding as of July 10, 2026), underscoring potential dilution and market overhang. Cadrenal’s auditors note substantial doubt about its ability to continue as a going concern, and the company highlights significant capital needs, dilution from future financings, warrant-related cash obligations in certain transactions, and large potential resales as key risks.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The resale proceeds will go to the selling stockholders; the company will receive proceeds only from any cash exercise of the warrants. The prospectus states 3,078,247 shares were outstanding as of April 1, 2026 and assumes 4,258,250 shares outstanding after full exercise.